This cross-sectional study examines conformance to four of the Schizophrenia Patient Outcomes Research Team (PORT) antipsychotic treatment recommendations, patient and treatment setting characteristics assocated with conformance, and the relationship of conformance with outcome. Two hundred twenty-four inpatients and 358 outpatients with schizophrenia underwent an interview and review of their medical records. Demographic, clinical, and role function data were collected. Almost all inpatients and outpatients with schizophrenia or schizoaffective disorder were prescribed an antipsychotic. The majority of inpatients were prescribed an antipsychotic within the recommended dose range, whereas the majority of outpatients were prescribed an antipsychotic either below or above the recommended dose range. There were no consistent relationships between patient, geographic, and treatment characteristics and antipsychotic dose. Patients treated with conventional antipsychotic doses below the recommended dose range had significantly better role function. Prospective longitudinal studies are required to delineate the factors that may underlie this relationship.
The PORT project conducted an extensive review of all studies investigating the use of antipsychotic agents for the treatment of schizophrenia (Buchanan 1995; Dixon et al. 1995; Umbricht and Kane 1995) . Specific areas reviewed included the efficacy and effectiveness of (1) conventional antipsychotics for the treatment of acute episodes and maintenance treatment, and (2) the new generation of antipsychotics-clozapine and risperidone. The review led to the development of 15 treatment recommendations for the use of antipsychotics in the acute and maintenance treatment of patients with schizophrenia (Lehman et al. 1998a) .
The majority of studies upon which the PORT pharmacotherapy treatment recommendations are based are clinical efficacy studies. There is little information on the extent of conformance to these recommendations. In a group of patients with schizophrenia and other psychotic disorders, Lehman and colleagues were able to examine the extent of conformance to 4 of the 15 antipsychotic treatment recommendations (Lehman et al. 1998£>) . They found that the highest conformance rates were for the first-line use of antipsychotics in the acute treatment of positive symptoms (89.2%) and the maintenance treatment of positive symptoms (92.3%), whereas the lowest rates were for conformance with the recommended antipsychotic dose in either the acute treatment of positive symptoms (62.4%) or the maintenance treatment of positive symptoms (29.1%). In contrast, Chen et al. (2000) observed in a mainly male, older sample recruited from a Veteran Affairs medical center that only 77 percent of patients with schizophrenia were prescribed an antipsychotic for an acute episode; 61 percent of the patients were within the recommended dose range. There is almost no information on what patient and system of care characteristics influence conformance with these treatment recommendations. Chen et al. (2000) reported that patients who were treated with a conventional antipsychotic were more likely to be prescribed a dose below the recommended dose range, whereas patients treated with a newgeneration antipsychotic were more likely to be prescribed a dose within the recommended range. They also observed that patient age was inversely associated with antipsychotic dose. Patient ethnicity, gender, and distance from the treatment center were unrelated to conformance to any of the acute episode treatment recommendations.
Send reprint requests to Dr. R.W. Buchanan, Maryland Psychiatric Research Center, P.O. Box 21247, Baltimore, MD 21228; e-mail: rwbuchanan@mprc.umaryland.edu. There is no published information on whether conformance with these recommendations influences patient outcome in actual clinical practice. The lack of data on the impact of treatment recommendations on patient outcome precludes informed decision making concerning possible interventions designed to enhance quality of care through increased treatment recommendation conformance.
The current study was designed to examine (1) the rate of conformance of patients with schizophrenia or schizoaffective disorder to four of the PORT antipsychotic treatment recommendations; (2) the relationship of treatment recommendation conformance to demographic and clinical characteristics; and (3) the relationship of treatment recommendation conformance to patient outcome.
Methods
Sample. The PORT sampling procedures are described in detail elsewhere (Lehman et al. 1998&) . In brief, inpatient and outpatient treatment sites in two States that met a priori selection criteria were identified and asked to participate in the PORT project. The sites were in one southern and one midwestern State and included urban and rural treatment programs. There were two study samples: (1) an inpatient sample, which included patients who had been recently hospitalized with a presumptive diagnosis of schizophrenia; and (2) an outpatient sample, which included patients who were receiving their care in community-based treatment settings. Inpatients and outpatients who had a presumptive diagnosis of either schizophrenia or schizoaffective disorder, could speak English, were 18 years of age or older, and were legally competent were eligible for study participation. In addition, inpatient sample subjects were required to have spent at least one night in the hospital and to live within a specified geographic region. Patients who met these eligibility criteria were then asked to undergo an interview and a medical record review. A total of 663 inpatients met initial eligibility criteria for study participation. Of these, 458 agreed to have their names released to the study, 398 subjects met a more detailed eligibility assessment, and 279 of these underwent the study assessments. A total of 1,017 outpatients met initial eligibility criteria for study participation, 584 subjects agreed to have their names released to the study, 550 subjects met a more detailed eligibility assessment, and 440 of these underwent the study assessments.
The current study sample is a subset of the above sample. The following additional inclusion/exclusion criteria were applied: patients without a diagnosis of schizophrenia or schizoaffective disorder in the medical record abstraction (n = 49) and all subjects greater than 64 years old (n = 42) were excluded from the study. The latter exclusion criterion was added because pharmacological practices may differ for elderly patients. Thus, 628 (87.3%) of the 719 patients who were included in the original Lehman and colleagues report (19986) are included in the current study sample. All subjects provided written informed consent before study entry. They were interviewed between December 1994 and March 1996.
Patient Assessments. Three data collection instruments were created specifically for this project: (1) the PORT Mental Health Survey, a 90-minute client interview; and (2) two medical record abstraction forms-the PORT Inpatient Record Review and the PORT Outpatient Record Review. The PORT Mental Health Survey is largely based on the Quality of Life Interview (Lehman 1983) . The PORT Mental Health Survey also contains the Alcohol and Drug CAGE questions (Midanik et al. 1998) and selected items from the Hopkins Symptom Checklist (SCL-90; Derogatis et al. 1973) . The PORT Mental Health Survey obtains information on demographics, social and family relationships, living arrangements, daily activities and functioning, employment, financial resources, legal issues, health status, service use, patient knowledge, life satisfaction, symptoms, medication side effects, and alcohol and drug use. The PORT Outpatient and Inpatient Record Reviews obtain information on the patient's psychiatric and medical history and diagnoses, health services utilization, treatment plan, current medications, and family contacts and services.
Treatment Recommendations. The PORT treatment recommendations are based on an extensive review of the treatment literature and expert opinion (Buchanan 1995; Dixon et al. 1995; Umbricht and Kane 1995; Lehman et al. 1998a ). There are 15 treatment recommendations for using antipsychotics in the acute and maintenance pharmacological treatment of schizophrenia (Lehman et al. 1998a ). The PORT Inpatient and Outpatient Record Review and the PORT Mental Health Survey provided sufficient data to assess conformance with four of these treatment recommendations (TRs; the recommendation number in parentheses is the number used in Lehman et al. 1998a) : TR 1-acute inpatient antipsychotic treatment (recommendation 1); TR 2-acute inpatient antipsychotic dose (recommendation 2); TR 3-maintenance outpatient antipsychotic treatment (recommendation 8); and TR 4-maintenance outpatient antipsychotic dose (recommendation 9). For purposes of the current study, we have modified TR 1 and TR 3 to allow any antipsychotic, including clozapine, and we have clarified that "psychotic symptoms" refers to positive psychotic symptoms. The treatment recommendations, conformance criteria, and data source used to document conformance are listed in table 1. The current dose of antipsychotic is in the 300-600 CPZE/day range. It is not possible to assess attempts to lower doses higher than 600 CPZE/day or reasons for doses outside of the 300-600 CPZE/day range. Data source: PORT Outpatient Record Review.
Note.-CPZE = chlorpromazine equivalents; PORT = Patient Outcomes Research Team.
Medication Variables. The PORT Inpatient and
Outpatient Record Reviews were the data sources for medication information-the type, dosage, and route of administration of antipsychotic medications. The type of antipsychotics included all conventional antipsychotics and two new-generation antipsychotics: clozapine (released in 1990) and risperidone (released in 1994). The study data collection occurred before the release of either olanzapine or quetiapine. Patients were considered to be "conventional antipsychotic only" if they were treated with only an oral or depot conventional antipsychotic, and, similarly, "new-generation antipsychotic only" if they were treated with only either clozapine or risperidone. The average daily antipsychotic dose was calculated by multiplying the unit dosage in milligrams (mg) of the antipsychotic by the number of daily doses of the drug. If a patient was prescribed more than one antipsychotic, then the average daily dose was calculated for each medication and the total average dose was calculated by summing the individual average antipsychotic doses. The average daily antipsychotic doses were converted to chlorpromazine equivalents (CPZE) to allow them to be combined and compared across antipsychotic types and classes (Zito 1994) . The following conversions were used for clozapine and risperidone: clozapine 50 mg/day equals 100 CPZE and risperidone 1 mg/day equals 100 CPZE. These CPZE conversions are based on clinical trials demonstrating the efficacy of these drugs for positive symptoms (Kane et al. 1988; Marder and Meibach 1994; Peuskens 1995; Buchanan et al. 1998) . Patients receiving only oral medications were classified in the "only oral" category. If patients received only a depot formulation (i.e., either fluphenazine or haloperidol decanoate) or if they received a combination of an oral and depot antipsychotic, then they were classified in the "any depot" category. The following conversion rules were used to convert depot dosages into CPZEs: (1) fluphenazine decanoate: 25 mg every 3 weeks equals 665 CPZE (Zito 1994) ; and (2) haloperidol decanoate: 50 mg every 4 weeks equals 125 CPZE (Zito 1994 ).
Demographic and Clinical Variables.
The following demographic and clinical variables were used to evaluate the influence of patient, geographic, and treatment characteristics on conformance: patient age; gender; ethnicity (i.e., Caucasian versus non-Caucasian; the Hispanic and Asian subject sample sizes were too small to be analyzed separately and were included with the African-American subjects to form the non-Caucasian group); State (i.e., A or B); locale (i.e., urban or rural); diagnosis (i.e., schizophrenia, paranoid; schizophrenia, nonparanoid; or schizoaffective); duration of illness (defined as date of PORT Mental Health Survey interview minus age of onset); presence of substance abuse (i.e., either alcohol or drug abuse); and days hospitalized during the past year. The PORT Mental Health Survey was the data source for patient age, gender, ethnicity, duration of illness, State, and locale. The PORT Inpatient and Outpatient Record Reviews were the data source for diagnosis and schizophrenia subtype (i.e., paranoid or nonparanoid). The PORT Outpatient Record Review was the data source for days hospitalized during the past year. The presence of substance abuse was based on selected items from the PORT Mental Health Survey and the appropriate Record Review. The PORT Mental Health Survey provided information on self-report of substance use (two items), CAGE questions, and history of substance abuse treatment (two items) over the last year. The Record Reviews provided information on current substance abuse treatment (three items for inpatients and two items for outpatients). Subjects were considered to have current alcohol abuse if they reported use of Antabuse or provided an affirmative response to two items, and current drug abuse if they reported use of methadone or an affirmative response to two items. If patients met criteria for either current alcohol abuse or current drug abuse, they were considered to be positive for the presence of substance abuse.
Outcome Measures. The following outcome measures were evaluated: positive psychotic symptoms, depressive symptoms, medication side effects, social functioning, occupational functioning, and general life satisfaction. The PORT Mental Health Survey SCL-90 items were used to construct a Positive Psychotic Symptom measure. Six items defined this construct: idea that someone else can control your thoughts; hearing voices that others do not hear; other people being aware of your private thoughts; having thoughts that are not your own; feeling that most people cannot be trusted; and feeling that you are watched or talked about by others. The first four items were taken from the SCL-90 psychoticism factor, and the other two items were taken from the paranoid ideation factor. The complete psychoticism factor was not used in the current study, because it contains items that are not related to positive psychotic symptoms (e.g., feeling lonely even when you are with people; thinking that you should be punished for your sins; never feeling close to another person) (Derogatis and Cleary 1977) . The internal consistency of this measure was acceptable (inpatient sample: Cronbach's alpha = 0.82; outpatient sample: Cronbach's alpha = 0.82). The SCL-90 depression factor items were used to assess depressive symptoms. The PORT Mental Health Survey items derived from the Quality of Life Interview were used to assess social and occupational functioning and general life satisfaction. Six items assessed the frequency and quality of social contacts with family members and friends. There were four categories of occupational functioning: paid employment/full-time student, volunteer/homemaker, structured day program/part-time student, and unemployed. For purposes of analysis, the first three categories of employment were combined and occupational functioning was classified as a categorical yes/no variable. General life satisfaction was assessed using a 7-point Likert scale ranging from 1 (terrible) to 7 (delighted). The eight self-report PORT Mental Health Survey medication side effect items were used to assess the presence of medication side effects. Outcome measure scores other than occupational functioning represent the mean of the item scores.
Statistical Analyses. Treatment recommendation conformance rates were evaluated as either yes or no and were determined separately for the inpatient and outpatient study samples. In addition, we examined the conformance rates, within each study sample, by class of antipsychotic (conventional only vs. new generation only). Chi-square statistics were used to assess conformance rate differences with respect to class of antipsychotic medication for patients treated with conventional only versus new generation only.
The relationship of treatment recommendation conformance to demographic and clinical variables and the relationship of treatment recommendation conformance to outcome variables were examined for the two antipsychotic dose range recommendations. The inpatient and outpatient samples were separated into three groups: (1) patients whose dosage was within the recommended dosage range, (2) patients whose dosage was below the recommended dosage range, and (3) patients whose dosage was above the recommended dosage range. Univariate logistic regression analyses were used to examine the relationship between conformance and demographic and clinical variables. Adjusted odds ratios for each demographic and clinical variable and a 95 percent confidence interval (CI) were estimated from exp(b) and exp(b ± 1.96 s.e.(b)), where b is the estimated logistic regression coefficient for the given demographic and clinical variable. The odds ratio can be interpreted approximately as the relative change in the probability of conformance associated with the presence versus absence of a categorical variable, or with a one-unit change in a continuous measure (e.g., age). Age, gender, ethnicity, and any other variables that had a p value less than 0.25 in the univariate analyses were then included in multiple regression analyses. No further variable selection was performed.
Analyses of variance (ANOVAs) (for continuous variables) or chi-square analyses (for categorical variables) were used to examine the relationships between treatment recommendation conformance and outcome variables. Secondary analyses were conducted, in which patients were grouped according to whether they were receiving conventional only or new generation only antipsychotics.
The analyses examining the relationship between treatment recommendation conformance and demographic and clinical variables and treatment recommendation conformance and outcome variables were not conducted for the acute inpatient (TR 1) and maintenance outpatient (TR 3) antipsychotic treatment recommendations because of the very high rate of conformance with these treatment recommendations (> 95%).
If patients were prescribed more than one conventional antipsychotic only or more than one new-generation antipsychotic only, then they were included in all analyses. However, if they were prescribed at least one conventional and one new-generation antipsychotic, then they were included in all primary analyses but excluded from secondary analyses comparing conventional antipsychotic only and new-generation antipsychotic only groups.
All patients had complete demographic data. Twelve subjects were missing duration of illness data.
These missing values were replaced with the mean value for the variable. These mean values were calculated separately by gender and inpatient versus outpatient status. There were no other missing demographic and clinical variable data. Several subjects were missing outcome data. These subjects were excluded from any analysis that examined the relationship between the outcome variable for which they had missing data and treatment recommendation conformance. However, they would be included in other analyses for which they had outcome data.
Results
Antipsychotic Dose. The total sample of interviewed patients who met study inclusion/exclusion criteria was 628. Twenty-eight of these subjects were excluded because they had missing or noninterpretable PORT Record Review information, nine subjects were excluded because of missing PORT Mental Health Survey information, and nine were excluded because they were clinical trial research subjects. Of the remaining 582 patients, 224 patients were included in the inpatient sample and 358 were included in the outpatient sample. The demographic and clinical characteristics for the inpatient and outpatient samples are presented in table 2.
Inpatient sample. The mean antipsychotic average daily dose was 888.0 ± 709.1 CPZE (n = 218); one inpatient was treated with an antipsychotic but the dose was not specified, and five inpatients were not receiving an antipsychotic. The mean average daily dose for patients who were treated with a conventional antipsychotic only was 941.1 ± 812.5 CPZE (n = 145), and the mean average daily dose for patients who were treated with a new-generation antipsychotic only was 683.0 ± 315.8 CPZE (n = 56). The actual clozapine average daily dose (mg/day) was 382.8 ± 172.9 (n = 16), and the actual risperidone average daily dose (mg/day) was 6.3 ± 2.6 (n = 39). One inpatient was treated with both clozapine and risperidone. Seventeen inpatients were treated with both a conventional and a new-generation antipsychotic (average daily dose: 1,110.3 ± 555.5 CPZE).
Outpatient sample. The mean antipsychotic average daily dose was 748.9 ± 708.5 CPZE (n = 344); 14 outpatients were not receiving an antipsychotic. The mean average daily dose for patients who were treated with a conventional antipsychotic only was 723.8 ± 756.3 CPZE (n = 246), and the mean average daily dose for patients who were treated with a new-generation antipsychotic only was 707.9 ± 338.3 CPZE (n = 76). The actual clozapine average daily dose (mg/day) was 393.9 ± 187.6 (n = 41), and the actual risperidone average daily dose (mg/day) was 6.1 ± 2.6 (« = 34). One outpatient was treated with both clozapine and risperidone. Twenty-two outpatients were treated with both a conventional and a new-generation antipsychotic (average daily dose: 1,172.0 ± 956.7 CPZE).
Conformance Rates. The treatment recommendation conformance rates are presented in table 3. The conformance rates ranged from a high of 97.8 for TR 1 to a low of 27.9 for TR 4. Lehman and colleagues (19986) reported similar rates for the total sample. Inpatient sample. The recommended acute inpatient antipsychotic dose range (TR 2) is 300-1,000 CPZE/day. The number (percentage) of patients who were below, within, or above the TR 2 recommended dose range was as follows: < 300 CPZE/day, 29 (13.3%); 300-1,000 CPZE/day, 135 (61.9%); and > 1,000 CPZE/day, 54 (24.8%). The mean (± standard deviation [SD]) CPZE within each dose range was as follows: < 300 CPZE/day, 175 ± 67; 300-1,000 CPZE/day, 669 ± 240; and > 1,000 CPZE/day, 1818 ± 793. If one considers those inpatients receiving conventional or new-generation antipsychotics only, then in inpatients receiving conventional antipsychotics only (« = 146), 23 (15.8%) were below, 87 (59.6%) were within, and 36 (24.7%) were above the recommended dose; and in inpatients receiving new-generation antipsychotics only (n = 56), 5 (8.9%) were below, 42 (75.0%) were within, and 9 (16.1%) were above the recommended dose. There was no significant conformance rate difference between the two classes of antipsychotics (X 2 = 4.2; df= 2; p = 0.12), and there was no significant conformance rate difference between those patients treated with risperidone and those treated with clozapine 2 Outpatient sample. The recommended maintenance outpatient antipsychotic dose range (TR 4) is 300-600 CPZE/day. The number (percentage) of patients who were below, within, or above the TR 4 recommended doses was as follows: < 300 CPZE/day, 103 (29.9%); 300-600 CPZE/day, 96 (27.9%); and > 600 CPZE/day, 145 (42.1%). The mean (± SD) CPZE within each dose range was as follows: < 300 CPZE/day, 164 ± 69; 300-600 CPZE/day, 472 ± 104; and > 600 CPZE/day, 1,348 ± 726.
In outpatients receiving conventional antipsychotics only (n = 246), 95 (38.6%) were below, 56 (22.8%) were within, and 95 (38.6%) were above the recommended dose; and in outpatients receiving new-generation antipsychotics only (n = 76), 7 (9.2%) were below, 33 (43.4%) were within, and 36 (47.4%) were above the recommended dose. There was a significant difference between the two antipsychotic classes in the number of outpatients who were below, within, and above the recommended dose range (x 2 = 25.9; df=2;p = 0.001), with a greater number of outpatients receiving conventional antipsychotics only being below and a greater number of outpatients receiving new-generation antipsychotics only being above the recommended dose range. The conformance rate difference between conventional antipsychotics only and new-generation antipsychotics only was largely the result of the large number of patients treated with clozapine (26/41; 63.4%) who were above the recommended dose range. In contrast, only 9/34 (26.5%) of patients treated with risperidone were above the recommended dose range. The conformance rate difference between patients treated with risperidone and patients treated with clozapine was significant (x 2 = 14.1; df = 2; p = 0.001). Inpatient sample. In a comparison of inpatients whose prescribed antipsychotic dose was below versus within the recommended antipsychotic dose (TR 2), patients of Caucasian ethnicity (odds ratio [OR]: 0.41 (95% CI: 0.18-0.94); x 2 = 4.60; df = 1; p = 0.03) and patients who had a longer duration of hospitalization (OR: 0.34 (95% CI: 0.11-1.05); x 2 = 3.77; df = 1; p = 0.05) were more likely to be below rather than within the recommended dose range. The multiple regression model was significant (x 2 = 16.7; df= 8; p = 0.03), and ethnicity was the only variable that significantly contributed to the model (OR: 0.38 (95% CI: 0.15-0.95)). There were no significant relationships between any of the demographic and clinical variables and conformance for inpatients whose prescribed antipsychotic dose was within or above the recommended dose range.
Relationship of Antipsychotic Dose Treatment
Outpatient sample. In a comparison of outpatients whose prescribed antipsychotic dose was below versus within the recommended antipsychotic dose (TR 4), patients with nonparanoid (OR: 0.48 (95% CI: 0.22-1.04)) and paranoid schizophrenia (OR: 0.36 (95% CI: 0.16-0.78)) were more likely than patients with schizoaffective disorder to be within rather than below the recommended dose range (x 2 = 7.04; df= 2;p = 0.03). In a comparison of outpatients whose prescribed antipsychotic dose was within and above the recommended antipsychotic dose (TR 4), patients treated in an urban setting were almost twice as likely as those treated in a rural setting to be above rather than within the recommended dose range (OR: 1.98 (95% CI: 1.07-3.66); x 2 = 4.71; df = 1; p = 0.03). In both comparisons, the multiple regression models were not significant.
Relationship of Antipsychotic Dose Treatment Recommendation Conformance and Outcome.
Outcome measure data are presented in tables 5 and 6. Inpatient sample. There were no significant relationships between TR 2 conformance and any of the out- Note.-CPZE = chlorpromazine equivalents; SD = standard deviation. 1 Lower score is better.
2 Higher score is better.
4 n= 135.
5 n = 54.
6 n= 132.
7 n = 52. Note. CPZE = chlorpromazine equivalents; SD = standard deviation. come measures. In the secondary analyses, in inpatients who were receiving conventional antipsychotics only, there was a significant relationship between TR 2 conformance and medication side effects (F = 6.89; df-2,140; p = 0.001). In contrast, the relationship between TR 2 conformance and medication side effects was not significant in inpatients receiving new-generation antipsychotics only (F = 1.38; df= 2,51; p = 0.26). Post hoc analysis revealed that the relationship between TR 2 conformance and medication side effects in inpatients receiving conventional antipsychotics only was due to significantly increased medication side effects in inpatients who were treated within the recommended dose range (1.9 ± 0.5) as compared to those who were treated below the recommended dose range (1.5 ±0.3).
There was also a significant relationship between treatment recommendation conformance and social functioning in inpatients receiving conventional antipsychotics only (F = 4.00; df = 2,140; p = 0.02); this relationship was not significant in inpatients who were receiving new-generation antipsychotics only (F = 1.90; df = 2,53; p = 0.16). Post hoc analyses revealed that inpatients who were receiving conventional antipsychotics only and were treated with < 300 CPZE/day (3.0 ±0.8) had a significantly higher level of social functioning than inpatients treated within the recommended dose range (2.5 ± 0.9).
There were no other significant relationships between antipsychotic dose treatment recommendation conformance and outcome in either the conventional antipsychotic only or new-generation antipsychotic only inpatient groups.
Outpatient sample. The only significant relationship was between TR 4 conformance and SCL-90 positive psychotic symptoms (F = 3.65; df-2,354 ; p = 0.03); outpatients treated with > 600 CPZE/day had a significantly higher level of positive symptoms than outpatients treated with < 300 CPZE/day.
In secondary analyses, there was a significant relationship between treatment recommendation conformance and occupational functioning in outpatients who were receiving conventional antipsychotics only (x 2 = 8.12; df = 2; p = 0.02); this relationship was not significant in inpatients who were receiving new-generation antipsychotics only (x 2 = 2.58; df=2;p = 0.28). Post hoc analyses revealed that outpatients who were receiving conventional antipsychotics only and were treated with < 300 CPZE were more likely to be employed (61%) than outpatients treated with > 600 CPZE/day (40%).
There were no other significant relationships between antipsychotic dose treatment recommendation conformance and outcome in either the conventional antipsychotic only or new-generation antipsychotic only outpatient groups.
Conclusions
The Schizophrenia PORT treatment recommendations stipulate that antipsychotics should be used within specific dose ranges to treat the positive psychotic symptoms of inpatients and outpatients with schizophrenia and schizoaffective disorder. In the current study, the majority of inpatients (62%) were prescribed an antipsychotic within the recommended dose range; 13 percent were prescribed an antipsychotic below and 25 percent were prescribed an antipsychotic above the recommended dose range. Chen et al. (2000) observed an almost identical conformance rate (61%), with 35 percent of subjects prescribed an antipsychotic below and 4 percent prescribed an antipsychotic above the recommended dose range. In contrast to the inpatient sample, only 28 percent of the outpatients were prescribed an antipsychotic within the recommended dose range; 30 percent were prescribed an antipsychotic below and 42 percent were prescribed an antipsychotic above the recommended dose range. The difference in conformance rate between the two samples reflects largely the difference in the upper limit of the inpatient and outpatient dose ranges. The upper limit of the inpatient dose range is 1,000 CPZE/day, whereas the upper limit of the outpatient dose range is 600 CPZE/day. The mean antipsychotic average daily dose for the inpatient sample (888.0 ± 709.1) was actually greater than the mean antipsychotic average daily dose for the outpatient sample (748.9 ± 708.5), and a similar percentage of inpatients (75%) and outpatients (79%) were receiving antipsychotic doses less than or equal to 1,000 CPZE/day.
There were relatively few outpatients who were treated within the recommended dose range. The study results do not provide an easy explanation for this lack of conformance. None of the multiple regression analyses examining the relationship among clinical, demographic, and treatment-setting variables and treatment recommendation conformance were significant. The lack of relationships suggests that other variables may be more important correlates of current antipsychotic dose. For example, previous treatment history may be the most important determinant of prescribed dose. The clinical relevance of enhancing conformance to the maintenance outpatient antipsychotic dose recommendation will eventually depend on the delineation of the causal relationships between dose and outcome.
The stipulation of recommended antipsychotic dose ranges is designed to maximize treatment response and to minimize the adverse effects associated with antipsychotic treatment. The PORT dose range recommendations are based on the results of previous efficacy studies. The current study attempted to address the effectiveness of the proposed inpatient and outpatient dose ranges by examin-ing the relationship between antipsychotic dose and outcome. Inpatients treated with conventional antipsychotic doses below the recommended dose range were less likely to experience medication side effects and were more likely to have better social functioning. Outpatients treated with conventional antipsychotic doses below the recommended dose range were more likely to be employed. There were no significant adverse effects associated with low-dose treatment. These results suggest that treatment with antipsychotic doses below the recommended dose range may be clinically appropriate for some patients and are consistent with the predicted benefits of low-dose antipsychotic treatment (Carpenter et al. 1990; Buchanan and Carpenter 1996) . However, previous controlled clinical trials of low-dose strategies have not been able to demonstrate that these strategies are associated with improved role functioning (Carpenter et al. 1990; Schooler et al. 1997 ). Rather, low antipsychotic doses have been associated with increased rates of relapse and hospitalization (Carpenter et al. 1990; Dixon et al. 1995; Schooler et al. 1997) . The difference between previous efficacy studies and the current study results raises the question about the direction of any possible causal relationship between antipsychotic dose and outcome. Perhaps patients with intact role function receive lower antipsychotic doses because they are more treatmentresponsive and have fewer residual symptoms. In the current study, outpatients treated with low antipsychotic doses had significantly fewer positive symptoms. Alternatively, patients with intact role function may be less tolerant of higher antipsychotic doses. There were no significant differences in outcomes between patients treated within the recommended dose range and those treated with antipsychotic doses above the recommended dose range.
There were no significant relationships between conformance to new-generation antipsychotic dose range recommendations and outcome. The failure to observe any relationships between new-generation antipsychotic dose and outcome may be related to the relatively small number of subjects in the current study who were prescribed these drugs, rather than the absence of associations between dose and outcome. However, in none of the analyses where conventional antipsychotic dose range conformance was significantly related to an outcome measure did the relationship between new-generation antipsychotic dose range recommendation conformance and the outcome measure even approach statistical significance.
There are several limitations of the current study. The most important of these is the cross-sectional nature of the study, which precludes an evaluation of the direction of the observed relationships among antipsychotic dose and outcome measures. Prospective longitudinal studies are required to determine whether lower antipsychotic doses lead to better functional outcomes or patients with good functional outcome are more responsive to antipsychotic treatment and require lower doses, and whether patients treated above the recommended dose range would have done as well if treated within or below the recommended dose range. In addition, the relatively small number of subjects treated with new-generation antipsychotics limits the ability of the current study to adequately address whether new-generation antipsychotic dose is associated with outcome. Finally, the small number of subjects who were not prescribed antipsychotics precludes the direct examination of the impact of antipsychotic treatment per se on outcome.
In summary, a large percentage of patients with schizophrenia or schizoaffective disorder are being prescribed antipsychotics outside the recommended dose range. The patient or treatment-setting characteristics that are associated with the prescribed dose of antipsychotics are unclear. In contrast to previous results from controlled clinical trials, low conventional antipsychotic dose is associated with improved social and occupational outcome in this cross-sectional effectiveness study. Prospective longitudinal studies are required to delineate the factors that determine what dose a patient will be prescribed and that mediate the relationship between dose and social and occupational outcome.
